Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02252172




Registration number
NCT02252172
Ethics application status
Date submitted
11/08/2014
Date registered
30/09/2014
Date last updated
21/10/2024

Titles & IDs
Public title
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Scientific title
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Secondary ID [1] 0 0
54767414MMY3008
Secondary ID [2] 0 0
CR104762
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab IV
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab SC

Active comparator: Lenalidomide and Dexamethasone (Rd) - Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.

Active comparator: Daratumumab + Lenalidomide + Dexamethasone (DRd) - Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.


Treatment: Drugs: Daratumumab IV
Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).

Treatment: Drugs: Lenalidomide
Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.

Treatment: Drugs: Dexamethasone
Dexamethasone 40 mg orally or intravenously once in a week.

Treatment: Drugs: Daratumumab SC
Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary: Progression-free Survival (PFS)
Timepoint [1] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)
Secondary outcome [1] 0 0
Percentage of Participants With Complete Response (CR) or Better
Timepoint [1] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [2] 0 0
Percentage of Participants With Very Good Partial Response (VGPR) or Better
Timepoint [2] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [3] 0 0
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Timepoint [3] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [4] 0 0
Overall Response Rate (ORR)
Timepoint [4] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
From randomization to death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [6] 0 0
Time to Disease Progression (TTP)
Timepoint [6] 0 0
From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [7] 0 0
Time to Response
Timepoint [7] 0 0
From randomization to first response (PR or better) (up to 7.8 years)
Secondary outcome [8] 0 0
Duration of Response (DoR)
Timepoint [8] 0 0
From first response (PR of better) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [9] 0 0
Time to Subsequent Anti-myeloma Treatment
Timepoint [9] 0 0
From randomization to start of first subsequent anti-myeloma treatment, death, withdrawal of consent to study participation or CCO whichever is first (up to 7.8 years)
Secondary outcome [10] 0 0
Progression-free Survival on Next Line of Therapy (PFS2)
Timepoint [10] 0 0
From randomization to disease progression on first line of subsequent anti-myeloma therapy, death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)
Secondary outcome [11] 0 0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score to Day 1 of Cycle 3, 6, 9 and 12
Timepoint [11] 0 0
Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)
Secondary outcome [12] 0 0
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) to Day 1 of Cycle 3, 6, 9 and 12
Timepoint [12] 0 0
Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)
Secondary outcome [13] 0 0
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score to Day 1 of Cycle 3, 6, 9 and 12
Timepoint [13] 0 0
Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)

Eligibility
Key inclusion criteria
* Participant must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency, anemia and bone abnormalities) criteria, monoclonal plasma cells in the bone marrow greater than or equal to (>=) 10 percent (%) or presence of a biopsy proven plasmacytoma and measurable disease as defined by any of the following: (a) immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein [M-protein] level >=1.0 gram/deciliter [g/dL] or urine M-protein level >=200 milligram[mg]/24 hours[hrs]; or (b) IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level >=0.5 g/dL or urine M-protein level >=200 mg/24 hrs); or (c) light chain multiple myeloma without measurable disease in serum or urine (serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)
* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
* Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >=65 years; or participants less than (<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization
* Women of childbearing potential must commit to either abstain continuously from sexual intercourse or to use 2 methods of reliable birth control simultaneously as deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to dosing and must continue for 3 months after the last dose of daratumumab
* Man, who is sexually active with a woman of child-bearing potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for 4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumab
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (presence of serum M-protein <3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein), or smoldering multiple myeloma (asymptomatic multiple myeloma with absence of related organ or tissue impairment end organ damage)
* Participant has a diagnosis of Waldenström's disease, or other conditions in which IgM M protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
* Participant has a history of malignancy (other than multiple myeloma) within 5 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)
* Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatment
* Participant has had radiation therapy within 14 days of randomization
* Participant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] <50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years (controlled intermittent asthma or controlled mild persistent asthma is allowed)
* Participants with known or suspected COPD must have a FEV1 test during Screening
* Participant is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti-HCV antibody positive or HCV-ribonucleic acid [RNA] quantitation positive)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2024
Actual
Sample size
Target
Accrual to date
Final
737
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Box Hill
Recruitment hospital [2] 0 0
- Fitzroy
Recruitment hospital [3] 0 0
- Footscray
Recruitment hospital [4] 0 0
- Kogarah
Recruitment hospital [5] 0 0
- Kurralta Park
Recruitment hospital [6] 0 0
- Nedlands
Recruitment hospital [7] 0 0
- New South Wales
Recruitment hospital [8] 0 0
- Woodville
Recruitment hospital [9] 0 0
- Woolloongabba N/a
Recruitment postcode(s) [1] 0 0
- Box Hill
Recruitment postcode(s) [2] 0 0
- Fitzroy
Recruitment postcode(s) [3] 0 0
- Footscray
Recruitment postcode(s) [4] 0 0
- Kogarah
Recruitment postcode(s) [5] 0 0
- Kurralta Park
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment postcode(s) [7] 0 0
- New South Wales
Recruitment postcode(s) [8] 0 0
- Woodville
Recruitment postcode(s) [9] 0 0
- Woolloongabba N/a
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
New Hampshire
Country [21] 0 0
United States of America
State/province [21] 0 0
New Jersey
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
South Dakota
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
Austria
State/province [33] 0 0
Innsbruck
Country [34] 0 0
Austria
State/province [34] 0 0
Linz
Country [35] 0 0
Austria
State/province [35] 0 0
Salzburg
Country [36] 0 0
Austria
State/province [36] 0 0
Wien N/a
Country [37] 0 0
Austria
State/province [37] 0 0
Wien Wien
Country [38] 0 0
Belgium
State/province [38] 0 0
Brugge
Country [39] 0 0
Belgium
State/province [39] 0 0
Brussels
Country [40] 0 0
Belgium
State/province [40] 0 0
Brussel
Country [41] 0 0
Belgium
State/province [41] 0 0
Haine Saint Paul La Louviere
Country [42] 0 0
Belgium
State/province [42] 0 0
Leuven
Country [43] 0 0
Belgium
State/province [43] 0 0
Liege
Country [44] 0 0
Canada
State/province [44] 0 0
Alberta
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Canada
State/province [47] 0 0
N/a N/a
Country [48] 0 0
Canada
State/province [48] 0 0
Nova Scotia
Country [49] 0 0
Denmark
State/province [49] 0 0
Aarhus C
Country [50] 0 0
Denmark
State/province [50] 0 0
Odense
Country [51] 0 0
Denmark
State/province [51] 0 0
Vejle
Country [52] 0 0
France
State/province [52] 0 0
Amiens N/a Picardie
Country [53] 0 0
France
State/province [53] 0 0
Angers
Country [54] 0 0
France
State/province [54] 0 0
Bayonne Cedex
Country [55] 0 0
France
State/province [55] 0 0
Bretagne
Country [56] 0 0
France
State/province [56] 0 0
Caen
Country [57] 0 0
France
State/province [57] 0 0
Cergy Pontoise
Country [58] 0 0
France
State/province [58] 0 0
Chalons Sur Saone
Country [59] 0 0
France
State/province [59] 0 0
Clermont-Ferrand
Country [60] 0 0
France
State/province [60] 0 0
Creteil
Country [61] 0 0
France
State/province [61] 0 0
Dijon
Country [62] 0 0
France
State/province [62] 0 0
Dunkerque Cedex 1
Country [63] 0 0
France
State/province [63] 0 0
Grenoble Cedex 9
Country [64] 0 0
France
State/province [64] 0 0
La Roche sur Yon Cedex 9
Country [65] 0 0
France
State/province [65] 0 0
Le Chesnay Cedex
Country [66] 0 0
France
State/province [66] 0 0
Le Mans
Country [67] 0 0
France
State/province [67] 0 0
Lille Cedex
Country [68] 0 0
France
State/province [68] 0 0
Lille
Country [69] 0 0
France
State/province [69] 0 0
Limoges
Country [70] 0 0
France
State/province [70] 0 0
Lyon, Pierre-Benite
Country [71] 0 0
France
State/province [71] 0 0
Marseille Cedex 9
Country [72] 0 0
France
State/province [72] 0 0
Metz-Tessy
Country [73] 0 0
France
State/province [73] 0 0
Montivilliers
Country [74] 0 0
France
State/province [74] 0 0
Montpellier
Country [75] 0 0
France
State/province [75] 0 0
Mulhouse
Country [76] 0 0
France
State/province [76] 0 0
Nantes
Country [77] 0 0
France
State/province [77] 0 0
Nice N/a
Country [78] 0 0
France
State/province [78] 0 0
Paris Cedex 12
Country [79] 0 0
France
State/province [79] 0 0
Paris, 75
Country [80] 0 0
France
State/province [80] 0 0
Paris
Country [81] 0 0
France
State/province [81] 0 0
PERIGUEUX cedex
Country [82] 0 0
France
State/province [82] 0 0
Perpignan
Country [83] 0 0
France
State/province [83] 0 0
Pessac
Country [84] 0 0
France
State/province [84] 0 0
Poitiers
Country [85] 0 0
France
State/province [85] 0 0
Reims
Country [86] 0 0
France
State/province [86] 0 0
Rennes
Country [87] 0 0
France
State/province [87] 0 0
Rouen Cedex
Country [88] 0 0
France
State/province [88] 0 0
Saint Brieuc Cedex 1
Country [89] 0 0
France
State/province [89] 0 0
Saint Priest en Jarez
Country [90] 0 0
France
State/province [90] 0 0
St Malo Cedex
Country [91] 0 0
France
State/province [91] 0 0
St Quentin Cedex
Country [92] 0 0
France
State/province [92] 0 0
Strasbourg
Country [93] 0 0
France
State/province [93] 0 0
Toulouse Cedex 9
Country [94] 0 0
France
State/province [94] 0 0
TOURS Cedex 9
Country [95] 0 0
France
State/province [95] 0 0
Vandoeuvre Les Nancy
Country [96] 0 0
Germany
State/province [96] 0 0
Aschaffenburg
Country [97] 0 0
Germany
State/province [97] 0 0
Bad Berka
Country [98] 0 0
Germany
State/province [98] 0 0
Bonn
Country [99] 0 0
Germany
State/province [99] 0 0
Braunschweig
Country [100] 0 0
Germany
State/province [100] 0 0
Dresden
Country [101] 0 0
Germany
State/province [101] 0 0
Essen
Country [102] 0 0
Germany
State/province [102] 0 0
Frankfurt
Country [103] 0 0
Germany
State/province [103] 0 0
Hannover
Country [104] 0 0
Germany
State/province [104] 0 0
Heidelberg
Country [105] 0 0
Germany
State/province [105] 0 0
Hessen
Country [106] 0 0
Germany
State/province [106] 0 0
Kiel
Country [107] 0 0
Germany
State/province [107] 0 0
Koblenz
Country [108] 0 0
Germany
State/province [108] 0 0
Mainz
Country [109] 0 0
Germany
State/province [109] 0 0
Mannheim
Country [110] 0 0
Germany
State/province [110] 0 0
Rostock
Country [111] 0 0
Germany
State/province [111] 0 0
Schwerin
Country [112] 0 0
Germany
State/province [112] 0 0
Stuttgart
Country [113] 0 0
Germany
State/province [113] 0 0
Tuebingen
Country [114] 0 0
Germany
State/province [114] 0 0
Ulm
Country [115] 0 0
Germany
State/province [115] 0 0
Villingen-Schwenningen
Country [116] 0 0
Ireland
State/province [116] 0 0
Dublin
Country [117] 0 0
Ireland
State/province [117] 0 0
Galway
Country [118] 0 0
Israel
State/province [118] 0 0
Hadera
Country [119] 0 0
Israel
State/province [119] 0 0
Haifa
Country [120] 0 0
Israel
State/province [120] 0 0
Jerusalem
Country [121] 0 0
Israel
State/province [121] 0 0
Nahariya
Country [122] 0 0
Israel
State/province [122] 0 0
Petah Tikva
Country [123] 0 0
Israel
State/province [123] 0 0
Tel-Aviv
Country [124] 0 0
Netherlands
State/province [124] 0 0
Hilversum
Country [125] 0 0
Netherlands
State/province [125] 0 0
Hoofddorp
Country [126] 0 0
Netherlands
State/province [126] 0 0
Rotterdam
Country [127] 0 0
Netherlands
State/province [127] 0 0
Tilburg
Country [128] 0 0
Sweden
State/province [128] 0 0
Falun
Country [129] 0 0
Sweden
State/province [129] 0 0
Göteborg
Country [130] 0 0
Sweden
State/province [130] 0 0
Halmstad
Country [131] 0 0
Sweden
State/province [131] 0 0
Helsingborg
Country [132] 0 0
Sweden
State/province [132] 0 0
Huddinge
Country [133] 0 0
Sweden
State/province [133] 0 0
Lulea
Country [134] 0 0
Sweden
State/province [134] 0 0
Lund
Country [135] 0 0
Sweden
State/province [135] 0 0
Stockholm
Country [136] 0 0
Sweden
State/province [136] 0 0
Örebro
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Aberdeen
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Canterbury
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Dundee
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Leeds
Country [141] 0 0
United Kingdom
State/province [141] 0 0
London
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Manchester
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Nottingham
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Oxford
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Plymouth, Devon
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Southampton
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Truro
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).
Trial website
https://clinicaltrials.gov/study/NCT02252172
Trial related presentations / publications
Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H, Wroblewski S, Carson R, Delioukina M, White D. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. J Oncol Pharm Pract. 2023 Jul;29(5):1172-1177. doi: 10.1177/10781552221103551. Epub 2022 Sep 6.
Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101.
San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439.
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. Epub 2020 Dec 16.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02252172